Biomarkers of Oxidative Stress in Heart Failure

Heart Failure Clinics

Volumn 5, Issue 4, 2009, Pages 561-577

  Trachtenberg, Barry H ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Biomarkers; Heart failure; Isoprostane; Malonaldehyde; Myeloperoxidase; Oxidative stress; Oxidized LDL; Uric acid

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALLANTOIN; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BILIRUBIN DERIVATIVE; BIOLOGICAL MARKER; BIOPYRRIN; CARVEDILOL; FP 15; HEMOGLOBIN DERIVATIVE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; ISOPROSTANE; MALONALDEHYDE; METOPROLOL; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIPURINOL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; S NITROSOHEMOGLOBIN; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID; XANTHINE OXIDASE;

CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERURICEMIA; INFLAMMATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW;

BIOLOGICAL MARKERS; HEART FAILURE; HEMOGLOBINS; HUMANS; LIPOPROTEINS, LDL; OXIDATIVE STRESS; PEROXIDASE; URIC ACID;

EID: 67650601390     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.04.003     Document Type: Review

References (100)

1. Cave A.C., Brewer A.C., Narayanapanicker A., et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8 5-6 (2006) 691-728
2. Ungvari Z., Gupte S.A., Recchia F.A., et al. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3 3 (2005) 221-229
3. Zimmet J.M., and Hare J.M. Nitroso-redox interactions in the cardiovascular system. Circulation 114 14 (2006) 1531-1544
4. Hare J.M., and Stamler J.S. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115 3 (2005) 509-517
5. Spiekermann S., Landmesser U., Dikalov S., et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 107 10 (2003) 1383-1389
6. Morrow D.A., and de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115 8 (2007) 949-952
7. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286 17 (2001) 2136-2142
8. Nicholls S.J., Zheng L., and Hazen S.L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 15 6 (2005) 212-219
9. Vasilyev N., Williams T., Brennan M.L., et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112 18 (2005) 2812-2820
10. Brennan M.L., Penn M.S., Van L.F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 17 (2003) 1595-1604
11. Fu X., Kassim S.Y., Parks W.C., et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276 44 (2001) 41279-41287
12. Morrow D.A., Sabatine M.S., Brennan M.L., et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29 9 (2008) 1096-1102
13. Mocatta T.J., Pilbrow A.P., Cameron V.A., et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 49 20 (2007) 1993-2000
14. Tang W.H., Brennan M.L., Philip K., et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 98 6 (2006) 796-799
15. Tang W.H., Tong W., Troughton R.W., et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 49 24 (2007) 2364-2370
16. Ng L.L., Pathik B., Loke I.W., et al. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 152 1 (2006) 94-101
17. Shah K.B., Kop W.J., Christenson R.H., et al. Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. Clin Chem 55 1 (2009) 59-67
18. Kumar A.P., and Reynolds W.F. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 331 2 (2005) 442-451
19. Neuzil J., and Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 269 24 (1994) 16712-16719
20. Schwertner H.A., Jackson W.G., and Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40 1 (1994) 18-23
21. Hopkins P.N., Wu L.L., Hunt S.C., et al. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16 2 (1996) 250-255
22. Shimomura H., Ogawa H., Takazoe K., et al. Comparison of urinary biopyrrin levels in acute myocardial infarction (after reperfusion therapy) versus stable angina pectoris and their usefulness in predicting subsequent cardiac events. Am J Cardiol 90 2 (2002) 108-111
23. Hokamaki J., Kawano H., Yoshimura M., et al. Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol 43 10 (2004) 1880-1885
24. Yamamoto M., Maeda H., Hirose N., et al. Bilirubin oxidation provoked by nitric oxide radicals predicts the progression of acute cardiac allograft rejection. Am J Transplant 7 8 (2007) 1897-1906
25. Bessard J., Cracowski J.L., Stanke-Labesque F., et al. Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J Chromatogr B Biomed Sci Appl 754 2 (2001) 333-343
26. Proudfoot J., Barden A., Mori T.A., et al. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 272 2 (1999) 209-215
27. Li H., Lawson J.A., Reilly M., et al. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci U S A 96 23 (1999) 13381-13386
28. Kadiiska M.B., Gladen B.C., Baird D.D., et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic Biol Med 38 6 (2005) 698-710
29. Schwedhelm E., Bartling A., Lenzen H., et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 109 7 (2004) 843-848
30. Keaney Jr. J.F., Larson M.G., Vasan R.S., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23 3 (2003) 434-439
31. Reilly M.P., Pratico D., Delanty N., et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98 25 (1998) 2822-2828
32. Gross M., Steffes M., Jacobs Jr. D.R., et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem 51 1 (2005) 125-131
33. Polidori M.C., Pratico D., Savino K., et al. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 10 4 (2004) 334-338
34. Cracowski J.L., Tremel F., Marpeau C., et al. Increased formation of F(2)-isoprostanes in patients with severe heart failure. Heart 84 4 (2000) 439-440
35. Mallat Z., Philip I., Lebret M., et al. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97 16 (1998) 1536-1539
36. Pratico D., Tangirala R.K., Rader D.J., et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4 10 (1998) 1189-1192
37. De C.R., Cipollone F., Filardo F.P., et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 106 20 (2002) 2543-2549
38. Desideri G., Croce G., Tucci M., et al. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab 88 11 (2003) 5341-5347
39. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9 6 (1990) 515-540
40. Slatter D.A., Bolton C.H., and Bailey A.J. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 43 5 (2000) 550-557
41. Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 380 1-2 (2007) 50-58
42. Niskanen L.K., Salonen J.T., Nyyssonen K., et al. Plasma lipid peroxidation and hyperglycaemia: a connection through hyperinsulinaemia?. Diabet Med 12 9 (1995) 802-808
43. Tamer L., Sucu N., Polat G., et al. Decreased serum total antioxidant status and erythrocyte-reduced glutathione levels are associated with increased serum malondialdehyde in atherosclerotic patients. Arch Med Res 33 3 (2002) 257-260
44. Boaz M., Matas Z., Biro A., et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 34 3 (1999) 438-444
45. Pucheu S., Coudray C., Vanzetto G., et al. Assessment of radical activity during the acute phase of myocardial infarction following fibrinolysis: utility of assaying plasma malondialdehyde. Free Radic Biol Med 19 6 (1995) 873-881
46. Olsson K.A., Harnek J., Ohlin A.K., et al. No increase of plasma malondialdehyde after primary coronary angioplasty for acute myocardial infarction. Scand Cardiovasc J 36 4 (2002) 237-240
47. Diaz-Velez C.R., Garcia-Castineiras S., Mendoza-Ramos E., et al. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 131 1 (1996) 146-152
48. Polidori M.C., Savino K., Alunni G., et al. Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radic Biol Med 32 2 (2002) 148-152
49. Keith M., Geranmayegan A., Sole M.J., et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31 6 (1998) 1352-1356
50. Kukin M.L., Kalman J., Charney R.H., et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99 20 (1999) 2645-2651
51. Tingberg E., Ohlin A.K., Gottsater A., et al. Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy. Int J Cardiol 112 3 (2006) 275-281
52. Itabe H., and Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 14 1 (2007) 1-11
53. Shoji T., Nishizawa Y., Fukumoto M., et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 148 1 (2000) 171-177
54. Rietzschel E.R., Langlois M., De Buyzere M.L., et al. Oxidized low-density lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension 52 3 (2008) 535-541
55. Holvoet P., Vanhaecke J., Janssens S., et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98 15 (1998) 1487-1494
56. Nishi K., Itabe H., Uno M., et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 22 10 (2002) 1649-1654
57. Uno M., Kitazato K.T., Suzue A., et al. Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. Free Radic Biol Med 39 8 (2005) 1109-1116
58. Uno M., Harada M., Takimoto O., et al. Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement. Neurol Res 27 1 (2005) 94-102
59. Holvoet P., Mertens A., Verhamme P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21 5 (2001) 844-848
60. Ehara S., Naruko T., Shirai N., et al. Small coronary calcium deposits and elevated plasma levels of oxidized low density lipoprotein are characteristic of acute myocardial infarction. J Atheroscler Thromb 15 2 (2008) 75-81
61. Shimada K., Mokuno H., Matsunaga E., et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 174 2 (2004) 343-347
62. Wu T., Willett W.C., Rifai N., et al. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?. J Am Coll Cardiol 48 5 (2006) 973-979
63. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 1 (2005) 46-57
64. Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20 10 (2000) 2243-2247
65. Matsumoto T., Takashima H., Ohira N., et al. Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol 44 2 (2004) 451-457
66. Tsutsui T., Tsutamoto T., Wada A., et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 39 6 (2002) 957-962
67. Forster O., Hilfiker-Kleiner D., Ansari A.A., et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10 9 (2008) 861-868
68. Holvoet P., Van C.J., Collen D., et al. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20 3 (2000) 698-702
69. Ehara S., Ueda M., Naruko T., et al. Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases. J Diabetes Complicat 16 1 (2002) 60-64
70. Chen N.G., Azhar S., Abbasi F., et al. The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis 152 1 (2000) 203-208
71. Holvoet P., Lee D.H., Steffes M., et al. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299 19 (2008) 2287-2293
72. Ueba T., Nomura S., Nishikawa T., et al. Circulating oxidized LDL, measured with FOH1a/DLH3 antibody, is associated with metabolic syndrome and the coronary heart disease risk score in healthy Japanese. Atherosclerosis 203 1 (2009) 243-248
73. Sjogren P., Basu S., Rosell M., et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 25 12 (2005) 2580-2586
74. Feig D.I., and Johnson R.J. Hyperuricemia in childhood primary hypertension. Hypertension 42 3 (2003) 247-252
75. Feig D.I., Soletsky B., and Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300 8 (2008) 924-932
76. Ioachimescu A.G., Brennan D.M., Hoar B.M., et al. Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study. Diabet Med 24 12 (2007) 1369-1374
77. Fang J., and Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283 18 (2000) 2404-2410
78. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107 15 (2003) 1991-1997
79. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113 11 (2006) 1424-1433
80. Kittleson M.M., St John M.E., Bead V., et al. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart 93 3 (2007) 365-367
81. Leyva F., Anker S.D., Godsland I.F., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19 12 (1998) 1814-1822
82. Leyva F., Chua T.P., Anker S.D., et al. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism 47 9 (1998) 1156-1159
83. Stull L.B., Leppo M.K., Szweda L., et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95 10 (2004) 1005-1011
84. Naumova A.V., Chacko V.P., Ouwerkerk R., et al. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol 290 2 (2006) H837-H843
85. Minhas K.M., Saraiva R.M., Schuleri K.H., et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 98 2 (2006) 271-279
86. Amado L.C., Saliaris A.P., Raju S.V., et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 39 3 (2005) 531-536
87. Baldus S., Mullerleile K., Chumley P., et al. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic Biol Med 41 8 (2006) 1282-1288
88. Baldus S., Koster R., Chumley P., et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med 39 9 (2005) 1184-1190
89. Cappola T.P., Kass D.A., Nelson G.S., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104 20 (2001) 2407-2411
90. Hare J.M., Mangal B., Brown J., et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 51 24 (2008) 2301-2309
91. George J., Carr E., Davies J., et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114 23 (2006) 2508-2516
92. Doehner W., Schoene N., Rauchhaus M., et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105 22 (2002) 2619-2624
93. Hare J.M. Nitroso-redox balance in the cardiovascular system. N Engl J Med 351 20 (2004) 2112-2114
94. Datta B., Tufnell-Barrett T., Bleasdale R.A., et al. Red blood cell nitric oxide as an endocrine vasoregulator: a potential role in congestive heart failure. Circulation 109 11 (2004) 1339-1342
95. Maher A.R., Milsom A.B., Gunaruwan P., et al. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation 117 5 (2008) 670-677
96. Gonzalez F.M., Shiva S., Vincent P.S., et al. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation 117 23 (2008) 2986-2994
97. Eleuteri E, Di SA, Ricciardolo FL, et al. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int J Cardiol, in press.
98. Sesso H.D., Buring J.E., Christen W.G., et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 300 18 (2008) 2123-2133
99. Miller III E.R., Erlinger T.P., Sacks F.M., et al. A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: results from a randomized controlled feeding study. Atherosclerosis 183 1 (2005) 175-182
100. Opie L.H., and Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J 28 14 (2007) 1683-1693